1. 2700 Final results of ARIEL2 (Part 1): A phase 2 trial to prospectively identify ovarian cancer (OC) responders to rucaparib using tumor genetic analysis. Issue 3 (September 2015) Authors: Kristeleit, R.; Swisher, E.; Oza, A.; Coleman, R.L.; Scott, C.; Konecny, G.; Tinker, A.; O'Malley, D.M.; Brenton, J.; Bell-McGuinn, K.; Oaknin, A.; Leary, A.; Lin, K.K.; Raponi, M.; Giordano, H.; Maloney, L.; Goble, S.; Yelensky, R.; McNeish, I. Journal: European journal of cancer Issue: Volume 51:Issue 3(2015:Feb.) Page Start: S531 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Feasibility of monitoring response to the PARP inhibitor rucaparib with targeted deep sequencing of circulating tumor DNA (ctDNA) in women with high grade ovarian carcinoma on the ARIEL2 trial. (December 2016) Authors: Piskorz, A.M.; Lin, K.K.; Morris, J.; Mann, E.; Oza, A.; Coleman, R.L.; O'Malley, D.M.; Friedlander, M.; Cragun, J.M.; Ma, L.; Giordano, H.; Raponi, M.; McNeish, I.A.; Swisher, E.; Brenton, J.D. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S123 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗